NCT06040099
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06040099
Title A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (EMERALD-Y90)
Acronym EMERALD-Y90
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AstraZeneca
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Research Site Aurora Colorado 80045 United States Details
Research Site Gainesville Florida 32608 United States Details
Research Site Orlando Florida 32804 United States Details
Research Site Atlanta Georgia 30322 United States Details
Research Site Atlanta Georgia 30342 United States Details
Research Site Chicago Illinois 60611 United States Details
Research Site Boston Massachusetts 02118 United States Details
Research Site Detroit Michigan 48201 United States Details
Research Site St Louis Missouri 63110 United States Details
Research Site Trenton New Jersey 08690 United States Details
Research Site Buffalo New York 14263 United States Details
Research Site New York New York 10029 United States Details
Research Site Chapel Hill North Carolina 27599 United States Details
Research Site Columbus Ohio 43210 United States Details
Research Site Portland Oregon 97239 United States Details
Research Site Philadelphia Pennsylvania 19107 United States Details
Research Site Houston Texas 77030 United States Details
Research Site Charlottesville Virginia 22908 United States Details
Research Site Seattle Washington 98195 United States Details
Research Site Milwaukee Wisconsin 53215 United States Details
Research Site Milwaukee Wisconsin 53226 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field